223 related articles for article (PubMed ID: 32168325)
1. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.
Sevilla A; Morales MC; Ezkurra PA; Rasero J; Velasco V; Cancho-Galan G; Sánchez-Diez A; Mujika K; Penas C; Smith I; Asumendi A; Cortés JM; Boyano MD; Alonso S
PLoS One; 2020; 15(3):e0230136. PubMed ID: 32168325
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
3. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
4. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
Nielsen LB; Dabrosin N; Sloth K; Bønnelykke-Behrndtz ML; Steiniche T; Lade-Keller J
Histopathology; 2018 Apr; 72(5):814-825. PubMed ID: 29119584
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
[TBL] [Abstract][Full Text] [Related]
6. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
[TBL] [Abstract][Full Text] [Related]
7. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E mutation-specific antibody: A review.
Ritterhouse LL; Barletta JA
Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions.
Larsen AC; Dahl C; Dahmcke CM; Lade-Keller J; Siersma VD; Toft PB; Coupland SE; Prause JU; Guldberg P; Heegaard S
Acta Ophthalmol; 2016 Aug; 94(5):463-70. PubMed ID: 27009410
[TBL] [Abstract][Full Text] [Related]
10. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
11. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
12. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.
Lamy PJ; Castan F; Lozano N; Montélion C; Audran P; Bibeau F; Roques S; Montels F; Laberenne AC
J Mol Diagn; 2015 Jul; 17(4):366-73. PubMed ID: 25952101
[TBL] [Abstract][Full Text] [Related]
17. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.
Bucheit AD; Syklawer E; Jakob JA; Bassett RL; Curry JL; Gershenwald JE; Kim KB; Hwu P; Lazar AJ; Davies MA
Cancer; 2013 Nov; 119(21):3821-9. PubMed ID: 23922205
[TBL] [Abstract][Full Text] [Related]
19. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
